Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Down 37.9% in July

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 6,242 shares, a decline of 37.9% from the June 30th total of 10,049 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 12,727 shares, the short-interest ratio is presently 0.5 days.

Spectral Diagnostics Trading Down 0.3%

Shares of OTCMKTS EDTXF opened at $0.98 on Thursday. The stock has a market cap of $288.56 million, a P/E ratio of -9.83 and a beta of 0.11. Spectral Diagnostics has a twelve month low of $0.58 and a twelve month high of $1.31. The stock has a 50 day moving average of $0.98 and a two-hundred day moving average of $0.99.

Spectral Diagnostics (OTCMKTS:EDTXF) last announced its earnings results on Friday, May 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.